Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)
https://www.facingourrisk.org/research-clinical-trials/study/143/nivolumab-vs-placebo-combined-with-neoadjuvant-chemotherapy-adjuvant-endocrine-therapy-for-high-risk-er-her2-negative-breast-cancer-checkmate-7fl
Clinicaltrials.gov identifier:
NCT04109066 (https://clinicaltrials.gov/show/NCT04109066)
Newly-diagnosed, non-metastatic, ER-positive, HER2-negative breast cancer
Study Contact Information:
For more information about the study, visit:
bmsstudyconnect.com/us/en/clinical-trials/NCT04109066.html
About the Study
The CA209-7FL clinical trial is researching if a study drug combined with pre-surgery chemotherapy, surgery, and post-surgery endocrine therapy could be safe, effective, and improve outcomes for people with ER+, HER-negative breast cancer. This will be compared to a group that receives a placebo in addition to the same pre-surgery chemotherapy, surgery, and post-surgery endocrine therapy standard of care. NOTE: This study is no longer enrolling patients.
For more information about the study, visit: https://www.bmsstudyconnect.com/us/en/clinical-trials/NCT04109066.html
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To:
NOTE: This study is no longer enrolling patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.